TIS tissue therapies limited

relax regarding ce and website, page-6

  1. 492 Posts.
    Is there significant upside potential? yes.
    Is there significant downside potential? yes.

    How US trials are being funded is an unknown. Manufacturing costs appear to be incurred up to 9-12 months prior to sales, which may mean over the next couple of quarters cash burn will increase prior to cash receipts as increased quantities of VitroGrow for 2013-14 is manufactured. Capital adequacy is a concern.

    I am on the sidelines to preserve capital until some answers become clearer.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.